Cyclogest Leggangastíll 400 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

cyclogest leggangastíll 400 mg

gedeon richter plc.* - progesteronum inn - leggangastíll - 400 mg

Menopur Stungulyfsstofn og leysir, lausn 75 a.e. アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

menopur stungulyfsstofn og leysir, lausn 75 a.e.

ferring lægemidler a/s - menotrophin hp - stungulyfsstofn og leysir, lausn - 75 a.e.

Nexplanon (Implanon NXT 68 mg Vefjalyf) Vefjalyf 68 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

nexplanon (implanon nxt 68 mg vefjalyf) vefjalyf 68 mg

n.v. organon* - etonogestrelum inn - vefjalyf - 68 mg

Solu-Cortef Stungulyfsstofn og leysir, lausn 100 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-cortef stungulyfsstofn og leysir, lausn 100 mg

pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 100 mg

Solu-Cortef Stungulyfsstofn og leysir, lausn 250 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-cortef stungulyfsstofn og leysir, lausn 250 mg

pfizer aps - hydrocortisonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 250 mg

Solu-Medrol Stungulyfsstofn og leysir, lausn 40 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 40 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 40 mg

Solu-Medrol Stungulyfsstofn og leysir, lausn 125 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 125 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 125 mg

Solu-Medrol Stungulyfsstofn og leysir, lausn 500 mg アイスランド - アイスランド語 - LYFJASTOFNUN (Icelandic Medicines Agency)

solu-medrol stungulyfsstofn og leysir, lausn 500 mg

pfizer aps - methylprednisolonum natríumsúkkínat - stungulyfsstofn og leysir, lausn - 500 mg

Camcevi 欧州連合 - アイスランド語 - EMA (European Medicines Agency)

camcevi

accord healthcare s.l.u. - leuprorelin mesilate - blöðruhálskirtli - innkirtla meðferð - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Blincyto 欧州連合 - アイスランド語 - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - forvarnarfrumuæxli-eitilfrumuhvítblæði - Æxlishemjandi lyf - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.